Hematology (all articles)
First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022.
28 Mar, 2022 | 08:46h | UTC
RCT: Among critically ill patients with Covid-19, treatment with an antiplatelet agent had a low likelihood of improving organ support–free days within 21 days.
23 Mar, 2022 | 10:38h | UTCEditorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA
Commentary: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London
Commentaries on Twitter
https://twitter.com/JAMA_current/status/1506188937852858369
Guidelines on sickle cell disease: secondary stroke prevention in children and adolescents.
22 Mar, 2022 | 08:34h | UTC
Pro-Con Debate: Prehospital blood transfusion—should it be adopted for civilian trauma?
21 Mar, 2022 | 08:38h | UTCInfographic: Pre-Hospital Blood Transfusion: A Pro-Con Debate – Anesthesia & Analgesia
Valoctocogene Roxaparvovec gene therapy for Hemophilia A.
21 Mar, 2022 | 08:27h | UTCValoctocogene Roxaparvovec Gene Therapy for Hemophilia A – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Valoctocogene Roxaparvovec Evaluated in Severe Hemophilia A – HealthDay
Hemophilia A Gene Therapy Reduced Bleeding Events, Need for Clotting Factors – AJMC
Phase 2 RCT: Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia.
21 Mar, 2022 | 08:22h | UTCVenetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW: Results from the HOVON 139/GiVe, ph 2 trial show that consolidation with venetoclax after fixed-duration venetoclax + obinutuzumab in patients w/ previously untreated CLL increases known side-effects & does not prevent MRD and risk of relapse #lymsm https://t.co/VzCUSHPMrp pic.twitter.com/PB62XNLAIK
— The Lancet Haematology (@TheLancetHaem) March 2, 2022
Guideline: Management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period.
18 Mar, 2022 | 09:39h | UTC
Commentary on Twitter
BREAKING 🔥
Antiplatelets, anticoagulants and #EndoscopyNew CPG & dissemination tool.
An @AmCollegeGastro @CanGastroAssn co-production @AmJGastro and #JCAG@GriLeont @BryanGSauer @NeenaSAbrahamMD @alan_barkun @ThrombosisCan @LorenLaine2 #JenTelfordhttps://t.co/Ijs4jgOkPC pic.twitter.com/uUfN2zj3RS
— Journal of the Canadian Assn of Gastroenterology (@JCanAssnGastro) March 17, 2022
RCT: Efficacy of Plinabulin vs. Pegfilgrastim for prevention of docetaxel-induced neutropenia in patients with solid tumors.
18 Mar, 2022 | 08:00h | UTC
Commentary on Twitter
This RCT found that same-day plinabulin, a novel selective immunomodulating microtubule binding agent (SIMBA), is noninferior to next-day pegfilgrastim in chemotherapy-induced neutropenia prevention in patients receiving docetaxel chemotherapy. https://t.co/tUXuffISmB pic.twitter.com/LROsd3trPv
— JAMA Network Open (@JAMANetworkOpen) January 27, 2022
RCT: Bortezomib in newly diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
18 Mar, 2022 | 07:50h | UTCChildren’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
17 Mar, 2022 | 08:45h | UTC
Happy TRALIdays: An overview of trauma resuscitation and transfusion complications.
17 Mar, 2022 | 08:08h | UTCHappy TRALIdays: An Overview of Trauma Resuscitation and Transfusion Complications – emDocs
NCCN Guideline: T-Cell Lymphomas.
15 Mar, 2022 | 08:41h | UTC
Meta-analysis of randomized controlled trials comparing intraoperative red blood cell transfusion strategies.
14 Mar, 2022 | 01:47h | UTCRelated:
Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery
Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA
Meta-analysis of randomized trials: benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery.
10 Mar, 2022 | 10:48h | UTC
Commentary on Twitter
https://twitter.com/KariTikkinen/status/1501532156786577415
Perspective: Once viewed as a promising COVID-19 treatment, convalescent plasma falls out of favor.
10 Mar, 2022 | 10:47h | UTCOnce Viewed as a Promising COVID-19 Treatment, Convalescent Plasma Falls Out of Favor – JAMA
Safety and efficacy of antibiotic de-escalation and discontinuation in high-risk hematological patients with febrile neutropenia: a single-center experience.
10 Mar, 2022 | 10:09h | UTCRelated: Management of febrile neutropaenia: ESMO Clinical Practice Guidelines – Annals of Oncology
Commentary on Twitter
OFID: In high-risk hematological patients w/ febrile neutropenia, antibiotic de-escalation and discontinuation prior to neutrophil recovery did not lead to an increase in infectious complications. https://t.co/eUer1fmoc6 #IDSAJournals @PaulSaxMD @DrJLi @FungalDoc @jobadd pic.twitter.com/HuGRYA8YW3
— IDSA (@IDSAInfo) January 5, 2022
RCT: In patients with trauma-related hemorrhagic shock receiving prehospital care, there was no benefit from resuscitation with blood products compared to 0.9% sodium chloride.
9 Mar, 2022 | 09:55h | UTCInvited commentary: Prehospital blood transfusion: who benefits? – The Lancet Haematology
Commentary on Twitter
NEW research—resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care: results of #RePHILL, a randomised, controlled, phase 3 trial #openaccess #EmergencyMedicine 🚑🩸https://t.co/Ci0lMMCryX pic.twitter.com/iWEtV12N1r
— The Lancet Haematology (@TheLancetHaem) March 8, 2022
Review: Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies.
9 Mar, 2022 | 08:35h | UTC
Systematic Review: Anticoagulants for people hospitalized with COVID‐19.
7 Mar, 2022 | 00:48h | UTCAnticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Related: Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
M-A: Efficacy of covid-19 vaccines in immunocompromised patients.
4 Mar, 2022 | 10:01h | UTCNews Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom
Related: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.
Commentary on Twitter
NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav
— The BMJ (@bmj_latest) March 3, 2022
Guideline: Management of Clostridioides difficile infection in hematopoietic cell transplant recipients.
3 Mar, 2022 | 08:17h | UTCSee other articles in the series:
Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week.
2 Mar, 2022 | 09:03h | UTCCommentary: Review of Anticoagulation in Patients With COVID-19: Key Points – American College of Cardiology
SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients.
2 Mar, 2022 | 08:51h | UTC
Two large populational-based studies find a slightly increased risk of thrombotic events following AstraZeneca COVID-19 vaccination.
24 Feb, 2022 | 10:23h | UTCCommentaries:
Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax – TCTMD
Review: Cancer-associated venous thromboembolism.
21 Feb, 2022 | 08:42h | UTCCancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Related:
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.